*Transplant* 1993;8:235-239.
31. Holton DL, Nicolle LE, Diley D, Bernstein K. Efficacy of mupirocin nasal ointment in eradication of *Staphylococcus aureus* nasal carriage in chronic haemodialysis patients. *J Hosp Infect* 1991;17:133-137.
32. Kluytmans J, Manders MAAJ, vanBommel E, Verbrugh H. Elimination of nasal carriage of *Staphylococcus aureus* in hemodialysis patients. *Infect Control Hosp Epidemiol* 1996;17:793-797.
33. Boelaert JR, De Baere YA, Geernaert MA, Godard CA, VanLanduy HW. The use of nasal mupirocin ointment to prevent *Staphylococcus aureus* bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. *J Hosp Infect* 1991;19(suppl B):41-46.
34. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing *Staphylococcus aureus* infection in hemodialysis patients: a decision analysis. *Am J Kidney Dis* 1996;27:687-694.
35. Perez-Fontan M, Garcia-Falcon T, Rosales M, et al. Treatment of *Staphylococcus aureus* nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. *Am J Kidney Dis* 1993;22:708-712.
36. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of *Staphylococcus aureus* prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. *Am J Kidney Dis* 1996;27:695-700.
37. Swartz R, Messana J, Starmann B, Weber M, Reynolds J. Preventing *Staphylococcus aureus* infection during chronic peritoneal dialysis. *J Am Soc Nephrol* 1991;2:1085-1091.
38. Coovadia YM, Bhana RH, Johnson AP, Haffejee I, Marples RR. A laboratory-confirmed outbreak of rifampicin-methicillin resistant *Staphylococcus aureus* (RMRSA) in a newborn nursery. *J Hosp Infect* 1989;14:303-312.
39. Gaynes R, Marosok R, Mowry-Hanley J, et al. Mediastinitis following coronary artery bypass surgery: a 3-year review. *J Infect Dis* 1991;163:117-121.
40. Boyce JM, Opal SM, Potter-Bynoe G, Medeiros AA. Spread of methicillin-resistant *Staphylococcus aureus* in a hospital after exposure to a health care worker with chronic sinusitis. *Clin Infect Dis* 1993;17:496-504.
41. Sherertz RJ, Reagan DR, Hampton KD, et al. A cloud adult: the *Staphylococcus aureus*-virus interaction revisited. *Ann Intern Med* 1996;124:539-547.
42. Meier PA, Carter CD, Wallace SE, Hollis RJ, Pfaller MA, Herwaldt LA. Eradication of methicillin-resistant *Staphylococcus aureus* (MRSA) from the burn unit at a tertiary medical center. *Infect Control Hosp Epidemiol* 1996;17:798-802.
43. Wenzel RP, Nettleman MD, Jones RN, Pfaller MA. Methicillin-resistant *Staphylococcus aureus*: implications for the 1990s and effective control measures. *Am J Med* 1991;91(suppl 3B):221S-227S.
44. Boelaert JR, VanLanduyt HW, DeBaere YA, et al. Nasal mupirocin decreases the incidence of *Staphylococcus aureus* bacteremia in hemodialysis: a five-year study. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September 1995. Abstract J122.
45. Marples RR, Speller DCE, Cookson BD. Prevalence of mupirocin resistance in *Staphylococcus aureus*. *J Hosp Infect* 1995;29:153-161.
46. Kauffman CA, Terpenning MS, He X, et al. Attempts to eradicate methicillin-resistant *Staphylococcus aureus* from a long-term-care facility with the use of mupirocin ointment. *Am J Med* 1993;94:371-378.
47. Layton MC, Perez M, Heald P, Patterson JE. An outbreak of mupirocin-resistant *Staphylococcus aureus* on a dermatology ward associated with an environmental reservoir. *Infect Control Hosp Epidemiol* 1993;14:369-375.
48. Bradley SF, Ramsey MA, Morton TM, Kauffman CA. Mupirocin resistance: clinical and molecular epidemiology. *Infect Control Hosp Epidemiol* 1995;16:354-358.
49. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant *Staphylococcus aureus* (MRSA) after widespread use of nasal mupirocin ointment. *Infect Control Hosp Epidemiol* 1996;17:812-814.
50. dos Santos KRN, Fonseca LDS, Filho PPG. Emergence of high-level mupirocin resistance in methicillin-resistant *Staphylococcus aureus* isolated from Brazilian university hospitals. *Infect Control Hosp Epidemiol* 1996;17:814-816.

## VRE in Liver Transplant Recipients

**Gina Pugliese, RN, MS**
**Martin S. Favero, PhD**

Investigators at Mount Sinai Medical Center in New York City reported on a study of risk factors for acquisition of, and mortality due to, nosocomial infections with vancomycin-resistant *Enterococcus faecium* (VREF) in orthotopic liver transplant (OLT) recipients. Thirty-two VREF-infected OLT patients (cases) were compared with 33 randomly selected OLT recipients (controls). More antibiotics were administered preoperatively to cases (mean, 4 antibiotics per patient for 474 antibiotic-days) than controls (mean, 1.8 antibiotics per patient for 131 antibiotic-days). Cases were more likely than controls to have received vancomycin therapy preoperatively and to have been hospitalized in the intensive-care unit (ICU) preoperatively. Logistic regression revealed that the risk factors for acquisition of VREF infection were surgical reexploration and a prolonged stay in the surgical ICU postoperatively. In the cases, the risk factors for mortality were admission to the ICU preoperatively and hemodialysis. The mortality rate associated with polymicrobial bloodstream infections was 100% despite appropriate therapy. Sixteen and 18 cases received parenteral chloramphenicol and doxycycline, respectively, for treatment of VREF infection. There were no hematologic adverse effects attributed to chloramphenicol treatment. DNA analysis of selected *E faecium* isolates suggested that infections were due to multiple clones.

The authors concluded that antibiotic usage provides for a selection pressure that probably contributes to VREF colonization and that infection with VREF is a predictor of morbidity and mortality in OLT patients. The authors discourage the use of vancomycin as a perioperative prophylaxis in all institutions that still employ this practice.

FROM: Pananicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin resistant *Enterococcus faecium* in liver transplant recipients: risk factors for acquisition and mortality. *Clin Infect Dis* 1996;23:760-766.

https://doi.org/10.1017/S0195941700003453 Published online by Cambridge University Press